Hodgkin’s Lymphoma Market

Market Overview:

The hodgkin’s lymphoma market reached a value of USD 7.1 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 20.8 Billion by 2035, exhibiting a growth rate (CAGR) of 10.50% during 2025-2035.

The Hodgkin’s lymphoma market has been comprehensively analyzed in IMARC's new report titled "Hodgkin’s Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Hodgkin's lymphoma refers to a type of oncological disease that affects the lymphatic system, which is part of the body's immune system. The illness is characterized by the presence of large, atypical white blood cells within the lymph nodes. These cells contribute to the growth of the cancerous mass and the immune response associated with the illness. The most common symptom of the ailment is painless swelling of lymph nodes, mainly in the armpits, neck, or groin. Individuals suffering from this disease may also experience loss of appetite, fatigue, fever, night sweats, unexplained weight loss, itching, a persistent cough or feeling of breathlessness, etc. Hodgkin's lymphoma is typically diagnosed through a combination of medical history assessment, underlying indication review, and physical examination. During a physical exam, the healthcare provider will closely check any signs of enlarged lymph nodes, swelling, or other abnormalities. Blood tests are also recommended to measure certain disease markers, such as erythrocyte sedimentation rate and C-reactive protein, in patients. Additionally, a biopsy is generally utilized to confirm a diagnosis of the condition.

The increasing cases of genetic disorders, causing an alteration in the DNA of B lymphocytes, which are a particular form of white blood cells, are primarily driving the Hodgkin's lymphoma market. In addition to this, the rising incidence of several associated risk factors, including a weakened immune system, family history, chronic inflammation, Epstein-Barr virus infections, etc., is also propelling the market growth. Moreover, the emerging popularity of external beam radiation therapy on account of its numerous benefits over conventional chemotherapies, such as targeted treatment, fewer systemic side effects, and convenience, is acting as another significant growth-inducing factor. Additionally, the escalating application of stem cell transplantation to treat individuals suffering from relapsed or refractory disease conditions is further creating a positive outlook for the market. This procedure helps to replace cancerous cells with healthy blood-forming cells to reestablish a normal blood cell population. Furthermore, the inflating adoption of targeted therapies, like monoclonal antibodies, which are specifically designed to stop the growth and spread of tumors, is expected to drive the Hodgkin's lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Hodgkin’s lymphoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Hodgkin’s lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Hodgkin’s lymphoma market in any manner.

Recent Developments:

• In December 2024, Affimed GmbH disclosed data during a poster session at the 66th ASH Annual Meeting and Exposition. This dataset comprises 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. This trial assesses the safety and efficacy of acimtamig (AFM13) in combination with Artiva Biotherapeutics' allogeneic NK cell therapy, AlloNK, for individuals with relapsed or refractory classical Hodgkin lymphoma.

Key Highlights:

• Hodgkin lymphoma affects around one in every 25,000 people each year, accounting for slightly less than 1% of all malignancies that occur worldwide.
• Children under the age of five are extremely unlikely to have Hodgkin lymphoma. However, it is the most common cancer diagnosed in teenagers aged 15 to 19 years.
• Males are more prone than females to develop Hodgkin lymphoma, particularly in youngsters, with boys accounting for 85% of all cases.
• Females had a 2.9 times lower age-related incidence rate than males between the ages of 5 and 9.
• The 5- and 10-year survival rates are expected to be about 85% and 80%, respectively.

Drugs:

Adcetris (Brentuximab Vedotin) is an antibody-drug conjugate (ADC) composed of an anti-CD30 monoclonal antibody linked to a microtubule disrupting chemical, monomethyl auristatin E (MMAE). The ADC uses a linker system that is designed to be stable in the bloodstream yet release MMAE when internalized by CD30-positive tumor cells.

Opdivo (Nivolumab) is an anti-cancer drug used for treating Hodgkin's lymphoma. T cells, which are important white blood cells in the immune system's battle against cancer, have a receptor for programmed death-1 (PD-1), which it binds to as a monoclonal antibody. By generating programmed death-ligand 1 (PD-L1), which binds to the PD-1 receptor and prevents T-cell activity and proliferation, some cancer cells take advantage of the PD-1 pathway to elude immune responses. Nivolumab blocks this interaction, allowing T cells to remain active and enhancing the immune system's ability to combat tumors, ultimately aiding in the destruction of cancer cells.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Hodgkin’s lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Hodgkin’s lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Hodgkin’s lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Hodgkin’s lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Hodgkin’s lymphoma market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Hodgkin’s lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of hodgkin’s lymphoma across the seven major markets?
• What is the number of incident cases (2019-2035) of hodgkin’s lymphoma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of hodgkin’s lymphoma by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of hodgkin’s lymphoma by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with Hodgkin’s lymphoma across the seven major markets?
• What is the size of the Hodgkin’s lymphoma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Hodgkin’s lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Hodgkin’s Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Hodgkin’s lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Hodgkin’s lymphoma market?
• What are the key regulatory events related to the Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by status related to the Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by phase related to the Hodgkin’s lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the Hodgkin’s lymphoma market?